CoChat

Long‐term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma

Open access
Reeder, Craig B., Reece, Donna E., Kukreti, Vishal, Mikhael, Joseph R., Chen, Christine, Trudel, Suzanne, Laumann, Kristina, Vohra, Harjot, Fonseca, Rafael, Bergsagel, P. Leif, Leis, Jose F., Tiedemann, Rodger, Stewart, A. Keith · 2014 · British Journal of Haematology
Cited by 42

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

The past two decades have seen remarkable improvement in the outcomes for patients with multiple myeloma (MM) (Kumar et al, 2008). High dose melphalan and stem cell transplantation (SCT) has improved responses and lengthened survival (Harousseau et al, 2009). Advances in science have ushered in new classes of drugs including immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs). Combinations of these novel agents with the alkylating drugs (melphalan, cyclophosphamide) have improved and deepened responses over single agent therapy. A phase 2 clinical trial for newly diagnosed MM patients was conducted at Mayo Clinic Arizona (MCA) and Princess Margaret Hospital, Toronto (PMH), utilizing an induction regimen of cyclophosphamide, bortezomib and dexamethasone (CyBorD). This triplet combination produced rapid and deep responses in previous studies (Reeder et al, 2009, 2010). We report long-term follow-up data for all 63 patients treated on CyBorD at MCA and PMH. Eligible patients were ≥18 years of age with newly diagnosed multiple myeloma, had measurable disease, and had an Eastern Cooperative Oncology Group performance score ≤2, creatinine <309·4 μmol/l, absolute neutrophil count ≥1 × 109/l, and platelet count ≥ 1 × 109/l. All patients were symptomatic and needed therapy. All patients signed an informed consent. Sixty-three patients with newly diagnosed and symptomatic myeloma were enrolled between 2006 and 2008 on a phase 2 trial of weekly oral cyclophosphamide 300 mg/m2, IV bortezomib 1·3 mg/m2 days 1, 4, 8, 11 (Cohort 1) or 1·5 mg/m2 days 1, 8, 15, 22 (Cohort 2) and dexamethasone in high dose (Cohort 1) or high dose for 2 cycles, then low dose for 2 cycles (Cohort 2) in a 28 day cycle. Patients received prophylactic acyclovir and a quinolone antibiotic. Response after 4 cycles was the primary goal. Secondary goals were progression-free survival (PFS), overall survival (OS), toxicity of this combination and ability to harvest stem cells. Patients were stratified to high risk or standard risk by Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) criteria (Dispenzieri et al, 2007). It was assumed that most patients would proceed to SCT after stem cell collection and no maintenance after SCT was planned as part of the trial. Survival was calculated using the Kaplan Meier method. OS was defined as time from registration to death from any cause. PFS was defined as time from registration to progression or death. The trial was approved by the institutional review board/research ethics board of both treating centres and was monitored by the Mayo Clinic Cancer Center Data and Safety Monitoring Board. Data was frozen as of 26 February, 2014. The overall response (ORR) for all patients (n = 63) was 89% with 62% achieving a very good partial response (VGPR) or better. For patients completing all 4 cycles of therapy the ORR was 93% and with 67% in a VGPR or better. Forty-nine of 63 patients underwent autologous SCT after induction and 2 had a subsequent SCT after additional therapy (51/63, 81%). Maintenance therapy with either lenalidomide or thalidomide was administered in 18 patients (29%) due to concern for a high risk of early relapse in cytogenetic high-risk patients, and was at the discretion of the treating physician. The median PFS was 40·0 months. The 5-year PFS and OS rates were 42% (95% confidence interval [CI]: 31–57) and 70% (95%CI: 59–82) for the entire group (Fig 1). Twenty-four of the 63 patients were considered high risk (38%) and had responses equal to standard risk patients (88% vs. 90%, P = 1·0) However, the median PFS was shorter in high risk patients at 27·6 months vs. 55·7 months in the standard risk patients. High-risk patients had a 5-year PFS of 33% (95%CI: 19–59) vs. 48% (95%CI: 33–69) in the standard risk group. Likewise a lower OS rate (54% (95%CI: 37–78) vs. 81% (95%CI: 69–95)) (P = 0·04) was seen compared to standard risk patients (Fig 2). Combinations of 2, 3 or even 4 drugs have become common practice for induction therapy in newly diagnosed MM patients and can produce ORRs of ≥90%. Short term (1–2 years) survival with these doublet and triplet treatments is excellent, but long-term follow-up for many of the newer induction regimens has yet to be reported. Commonly used regimens employ bortezomib and dexamethasone alone (VD), or with either lenalidomide (VRD), thalidomide (VTD) or cyclophosphamide (CyBorD, VCD). The two platforms of carfilzomib with RD and RVD have generated ORR of 98% and 100%, respectively, with VGPR of 75% in both as part of prospective studies, pointing to the potent synergy of the PIs and IMiDs (Richardson et al, 2010; Jakubowiak et al, 2012). Whilst RVD is different to VRD in that both the schedule of dexamethasone is different as is the dose, which is less in the latter, VRD versus CyBorD showed similar outcomes (Kumar et al, 2012). Another common induction combination is lenalidomide and dexamethasone (RD). A comparison of RD, CyBorD and CRD

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.13004

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 42

Metadata

Authors
Reeder, C. B., Reece, D. E., Kukreti, V., Mikhael, J. R., Chen, C., Trudel, S., Laumann, K., Vohra, H., Fonseca, R., Bergsagel, P. L., Leis, J. F., Tiedemann, R., & Stewart, A. K.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2014-06-30
Volume
167
Issue
4
Pages
563-565
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1980168719
Cited by
42
References
2
FWCI
3.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.